| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2025 | Dec, 2025 | Dec, 2025 | Dec, 2025 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Medexus Pharmaceuticals Inc (MDP.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company. It is focused on auto-immune and pediatric diseases in the USA and Canada. The company's only reportable segment being the products sold and the marketing services offered to the pharmaceutical industry. Geographically, it derives a majority of revenue from the United States. Its product portfolio includes Rasuvo, Metoject, Rupall, Gliolan, and Treosulfan.
Fiscal Year End Date: 03/31